Letrozol Aristo® 2,5 mg

Description

Indications

• Advanced hormone-dependent breast cancer in postmenopausal women (first-line therapy).
• Early stages of invasive breast cancer (whose cells have hormone receptors) in postmenopausal women (as adjuvant therapy).
• Early-stage invasive breast cancer in postmenopausal women after completion of standard adjuvant therapy with tamoxifen for 5 years (as extended adjuvant therapy).
• Disseminated breast cancer in the development of recurrence or progression of disease in postmenopausal women (natural or artificially induced) who have received prior anti-estrogen therapy.

Contraindications

• Hypersensitivity to letrozole or any of the other components of the drug.
• Pre-menopause.
• Childhood and adolescence under 18 years of age.
• Endocrine condition characteristic of the reproductive period.

Caution

• Severe hepatic insufficiency (Child-Pugh class C).
• Severe renal insufficiency (creatinine clearance less than 10 ml/min).
• Concomitant use with potent inhibitors of CYP3A4 and CYP2A6 isoenzymes.
• Lactase deficiency, galactose intolerance, glucose-galactose malabsorption syndrome.